#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Michel Detheux Email
Co-founder, President & CEO . iTeos Therapeutics SA
Gosselies,
Locationm*************@iteostherapeutics.com
Primary EmailHow to contact Michel Detheux
Join and see Michel's contact info for free!Current Roles
Employees:
190Revenue:
$36.8MAbout
Starting operations in 2012, iTeos Therapeutics is a clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by developing immunotherapies by design. iTeos is developing EOS200271, a clinical-stage potent and selective IDO1 inhibitor with exceptional brain penetration. The company is also advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase 1 trial in the second half of 2018; and a human ADCC-enabling anti-TIGIT antibody (EOS884448), representing an additional, third clinical entry in 2019. Based in Gosselies, Belgium, iTeos Therapeutics was founded and supported in part by investments from the Ludwig Institute Cancer Research (LICR), the Walloon Region of Belgium and the European Fund for Economic and Regional Development (FEDER). For more information, please visit www.iteostherapeutics.com.iTeos Therapeutics SA Address
139 Main StreetGosselies, null